Renalytix plc (RNLXY) stock
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Renalytix gross margin
Gross margin is gross profit as a percentage of revenue.
Renalytix's gross margin for the twelve months ending Sep 30, 2024 was 12.7%. For fiscal 2024 it was 6.8%, against 21.2% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | 6.8% | −14.3 |
| FY2023 | Jun 30, 2023 | 21.2% | −8.3 |
| FY2022 | Jun 30, 2022 | 29.4% | −13.0 |
| FY2021 | Jun 30, 2021 | 42.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | 19.2% | +28.5 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | 6.1% | +36.1 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -12.3% | −29.0 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | 32.3% | −8.1 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -9.4% | −37.5 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -29.9% | −46.6 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | 16.7% | +1.1 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | 40.4% | −1.4 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | 28.2% | −24.7 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | 16.7% | +8.3 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 15.6% | −57.1 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | 41.8% | +6.0 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | 52.9% | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | 8.5% | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | 72.7% | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | 35.8% | – |
See a number that looks wrong?